# Hepatitis B Vaccination Policy Shift Risks Significant Infection Surge New modeling study warns that delaying infant vaccinations could increase chronic cases by 225 percent. - **Source:** [TIME](https://time.com/) - **Published:** 2026-10-19 - **Topic:** [Business](https://brifing.si/c/business) - **Original article:** - **On Brifing:** https://brifing.si/s/25ca2566-5ca1-4a64-9b97-1d3acf9ed022 ## Shift in Vaccination Policy In December 2025, the CDC moved away from recommending universal birth-dose hepatitis B vaccinations for infants born to negative-testing mothers. The new guidance promotes a shared decision-making model between parents and clinicians. This policy change allows for the first vaccine dose to be delayed until two months of age for specific infants. ## Modeling Potential Infection Risks A new study published in the Annals of Internal Medicine utilized computer modeling to simulate infection outcomes for a full year of U.S. births. Researchers analyzed 3.6 million children to project chronic hepatitis B rates over two decades. The simulation compared historical birth-dose protocols against the newly implemented shared decision-making vaccination scenarios. ## Projected Surge in Cases The study indicates that if vaccination rates drop to 26% under the new shared decision-making model, chronic hepatitis B cases could rise by 225%. Even with a 75% vaccination rate at two months, the model predicts a 19% increase in chronic infections compared to the standard practice of administering the dose at birth. ## Long-term Health Consequences Infants infected before age one face a 90% risk of developing chronic, lifelong hepatitis B. Left untreated, these early infections carry a one-in-four lifetime probability of developing liver cancer. Because the virus is often asymptomatic until liver failure or cancer occurs, delayed immunization poses a significant, silent threat to long-term public health outcomes. ## Economic and Systemic Impact Beyond individual health risks, delaying the first dose by two months is estimated to generate an additional $16.4 million in healthcare spending due to new infections. Researchers emphasize that these costs would compound annually if the policy remains unchanged, placing a persistent financial burden on the U.S. healthcare system and affected families. ## Professional and Legal Pushback The American Association of Pediatrics maintains its recommendation for universal birth-dose vaccination for all infants. Consequently, 15 states have filed lawsuits against the administration regarding these schedule changes. Professional medical societies continue to challenge the policy, arguing that established clinical evidence already confirms the efficacy and necessity of the original birth-dose protocol. ## Validation Through Existing Evidence Dr. Amir Mohareb notes that three recent modeling studies now corroborate the risks associated with delaying the birth dose. These findings provide sufficient evidence to avoid conducting new clinical trials on human subjects. Decades of prior research have already established the efficacy of the original approach, making further experimental testing unnecessary and unethical. ## Cumulative Public Health Risk The study highlights that the danger is not limited to a single birth cohort but accumulates over time. If the current vaccination guidelines persist, thousands of new chronic infections could emerge annually. This shift represents a departure from decades of medical progress, potentially reversing gains made in controlling the transmission of the virus. ## Sources covering this story - https://time.com/article/2026/10/19/hepatitis-b-vaccine-recommendations-study/ — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._